These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38885453)

  • 1. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
    Kathuria-Prakash N; Lopez LP; Raman S; Ye H; Anaokar J; Sisk A; Pantuck AJ; Drakaki A
    JCO Precis Oncol; 2024 Jun; 8():e2400154. PubMed ID: 38885453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
    Pal SK; Bergerot P; Dizman N; Bergerot C; Adashek J; Madison R; Chung JH; Ali SM; Jones JO; Salgia R
    Eur Urol; 2018 Jul; 74(1):124-128. PubMed ID: 29685646
    [No Abstract]   [Full Text] [Related]  

  • 3. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract]   [Full Text] [Related]  

  • 5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ALK Inhibitors in Patients With
    Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report.
    Varchetta V; Campanella C; Rossi M; Verzaro R; Vitale M; Soda G; Mancuso A
    Recenti Prog Med; 2021 Jan; 112(1):14e-15e. PubMed ID: 33512368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
    Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-rearranged renal cell carcinomas in Polish population.
    Gorczynski A; Czapiewski P; Korwat A; Budynko L; Prelowska M; Okon K; Biernat W
    Pathol Res Pract; 2019 Dec; 215(12):152669. PubMed ID: 31677810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
    Sun K; Nie L; Nong L; Cheng Y
    Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 18. Anaplastic Lymphoma Kinase Mutation (
    Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
    Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors.
    Mileham KF; Ahmad MN; Kim ES
    Oncology (Williston Park); 2019 Apr; 33(4):152-5. PubMed ID: 30990569
    [No Abstract]   [Full Text] [Related]  

  • 20. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.